An Year End Roundup Of Three FTSE 100 Stocks  – Hiscox Limited, AstraZeneca Plc And Ferguson Plc

  • Dec 23, 2019 GMT
  • Team Kalkine
An Year End Roundup Of Three FTSE 100 Stocks  – Hiscox Limited, AstraZeneca Plc And Ferguson Plc

Hiscox Limited

Hiscox Limited (LON: HSX) is an international insurance group headquartered in Bermuda. The organisation is currently working in 14 nations having 34 workplaces with a worker base of 3,300 experts. The organisation, through its subsidiaries, works in the continents of the United States, Asia, Europe, the United Kingdom and Bermuda. The organisation's business has been segmented into four reportable sections, which are Hiscox London Market, Hiscox Re, Hiscox Retail and Corporate Center. The company’s Retail segment contains the Hiscox United Kingdom & Ireland, Hiscox International and Hiscox Europe. The Hiscox division in the UK and Europe provide small- and medium-sized businesses with commercial insurance. The company’s Hiscox London Market division is primarily engaged in the insurance business internationally. The company’s Hiscox Re business is into reinsurance business and underwriting operations in Paris, London and Bermuda. The Corporate centre handles the management activities related to finance costs, administrative costs and investment return.

HSX Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 23-December-19, before the close of the market

As on 23rd December 2019, at 10:20 A.M Greenwich Mean Time, while writing, Hiscox Limited’s price of the stock was at GBX 1419.00 per stock on the London Stock Exchange, no change in value, as opposed to the last day’s closing price. While writing, the stock of Hiscox Limited has been trading 24.47 per cent above the 52-week low stock price, that was reportedly GBX 1140.00 per share, and was reached on November 07, 2019. At the time of writing, the stock price has been reported to be 20.95 per cent below the 52-week high price of GBX 1795.00, which the stock hit as on July 05, 2019. The company’s market capitalisation stood at a value of GBP 4.100 billion in relation to the present market price of the share of the company.

Reportedly, Hiscox Limited’s stock has given a downside return of around 8.75 per cent in value in the last one year, from the price of GBX 1555.00 per stock that the stocks set on December 24, 2018. The Hiscox Limited share has depicted a downside return in the previous half-year, of approximately 16.92 per cent from the price of the stock of GBX 1708.00 per stock that the company’s stock achieved on June 24, 2019. Hiscox Limited’s stock had also gained value by 11.64 per cent, in the previous month from the price of GBX 1271.00 per stock when the markets closed on November 22, 2019.

Company’s share beta was reported to be at a value of 0.50, which means the movement of the share of the company, has been less volatile, in comparison with the movement of the comparative benchmark index in the last one year.

AstraZeneca Plc

AstraZeneca Plc (LON: AZN) is a pharmaceutical and biotechnology organisation. It was established on April 1999 after the merger of Astra AB and Zeneca PL based out of Cambridge, the United Kingdom. The company is listed on London, New York and Stockholm exchanges, with the symbol AZN used in all the markets. The company has operations all over the world, with business spread in over 100 countries, and its medicines are consumed by millions of patients across the globe. The company’s core team works with the world’s leading academic, biotech research institutions and have a clinical collaboration with Immunomedics. In terms of product-based segments, the company’s core products segments are Oncology, Cardiovascular & Metabolic Disease (CVMD) as well as Respiratory, while the company also engages in the research and development around areas such as autoimmunity therapies, infections as well as neuroscience. The company’s Oncology division aims at expanding the treatment options for tumours and haematological cancers, using four key scientific platforms: Immuno-oncology (IO), Tumour drivers and resistance mechanisms, DNA damage response and Antibody-drug conjugates (ADC). In the Cardiovascular & Metabolic Disease (CVMD) segment, the company is expanding its portfolio into the cardiovascular-renal area and has more than 25 potential medicines and medicine combinations in its pipeline. The company’s prime business segments are in Europe, the United States of America as well as emerging markets, while it also runs operations in some of the other countries across the globe.

AZN Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 23-December-19, before the close of the market

As on 23rd December 2019, at 10:30 A.M Greenwich Mean Time, while writing, AstraZeneca Plc’s price of the stock was at GBX 7792.00 per stock on the London Stock Exchange, a decline in the value of 0.20 per cent or GBX 16.00 per stock, as opposed to the last day’s closing price, which was reported at GBX 7808.00 per stock. While writing, the stock of AstraZeneca Plc has been trading 46.69 per cent above the 52-week low stock price, that was reportedly GBX 5312.00 per share and was reached on January 28, 2019. At the time of writing, the stock price has been reported to be at 5.30 per cent below the 52-week high price of GBX 8227.88, which the stock hit as on October 07, 2019. The company’s market capitalisation stood at a value of GBP 102.434 billion in relation to the present market price of the share of the company.

The AstraZeneca Plc share has depicted an upside return in the previous half-year, of approximately 21.03 per cent from the price of the stock of GBX 6438.00 per stock that the company’s stock achieved on June 24, 2019. AstraZeneca Plc’s stock had also gained value by 5.04 per cent, in the previous month from the price of GBX 7418.00 per stock when the markets closed on November 22, 2019.

Company’s share beta was reported to be at a value of 0.80, which means that the movement of the share of the company, has been less volatile, in comparison with the movement of the comparative benchmark index in the last one year.

Ferguson Plc

Ferguson Plc (LON: FERG) is a Wokingham, the United Kingdom domiciled Industrial support services providing organisation that specialises and engages in the business of distribution of plumbing and heating products. The company, geographically, has two major divisions, which are the United States of America and International Businesses. In terms of International businesses, it basically operates in the Canadian as well as the United Kingdom markets. The company undertakes its various business operations with brand names such as Ferguson Enterprises for the United States of America market as well as Wolseley for the United Kingdom and Canadian markets and also it goes by the name of William Wilson specifically in the United Kingdom region. The United States of America market is the provider of the largest volume of business for the company with 92 per cent of the total trading profit of the company in 2019.

FERG Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 23-December-19, before the close of the market

As on 23rd December 2019, at 10:40 A.M Greenwich Mean Time, while writing, Ferguson Plc’s price of the stock was reported at GBX 7004.00 per stock on the London Stock Exchange, an increase in the value of 1.27 per cent or GBX 88.00 per stock, as opposed to the last day’s closing price, which was reported at GBX 6916.00 per stock. While writing, the stock of Ferguson Plc has been trading 52.46 per cent above the 52-week low stock price, that was reportedly GBX 4594.00 per share and was reached on March 26, 2019. At the time of writing, the stock price has been reported to be 0.37 per cent below the 52-week high price of GBX 7038.00, which the stock hit as on December 23, 2019. The company’s market capitalisation stood at a value of GBP 15.618 billion in relation to the present market price of the share of the company.

The Ferguson Plc share has depicted an upside return in the previous half-year, of approximately 22.75 per cent from the price of the stock of GBX 5706.00 per stock that the company’s stock achieved on June 24, 2019. Ferguson Plc’s stock had also lost value by 4.88 per cent, in the previous month from the price of GBX 6678.00 per stock when the markets closed on November 22, 2019.

Company’s share beta was reported to be at a value of 0.80, which means that the movement of the share of the company, has been less volatile, in comparison with the movement of the comparative benchmark index in the last one year.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK